Consensus Cipla Limited

Stocks

CIPLA

INE059A01026

Pharmaceuticals

Market Closed - NSE India S.E. 07:05:07 2026-09-08 am EDT			5-day change	1st Jan Change
1,384.00 ^INR	-0.79%		-1.79%	-8.42%

Sep. 03	India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar	RE
Aug. 25	Cipla's Pithampur, India Unit Gets 7 Observations From US FDA	MT

Evolution of the Average Target: Cipla Limited

Evolution of the Target Price: Cipla Limited

Changes in Analyst Recommendations: Cipla Limited

1b2694bb44d7711ca3a654ffc0fc4cc3.v_iPyAmDvZyM5vgDGqzewEVED9muyxCgfSNJmwMuw6k._YzVkFC30azV3rdGcZWdrTQVe6vXnkTkTVQj_jVbtpz3meaDR8_p-eG0nw~b03c9542a411970f49c0dbb9b125230f

Analysts' recommendations: Cipla Limited

Jul. 24	Jefferies Adjusts Cipla's Price Target to INR1,170 From INR1,120, Keeps at Underperform	MT
Jun. 24	Avendus Spark Upgrades Cipla to Buy from Add; Price Target is INR1,710	MT
May. 14	Elara Securities Downgrades Cipla to Reduce from Accumulate; Price Target is INR1,349	MT
May. 14	Elara Securities Downgrades Cipla to Sell from Neutral; Price Target is INR1,180	MT
May. 14	JM Financial Upgrades Cipla to Buy from Add; Price Target is INR1,546	MT
May. 14	Emkay Global Upgrades Cipla to Add from Reduce; Price Target is INR1,450	MT
May. 14	Avendus Spark Upgrades Cipla to Add from Reduce; Price Target is INR1,455	MT
May. 14	Nirmal Bang Downgrades Cipla to Hold from Buy; Price Target is INR1,404	MT
May. 08	Jefferies Adjusts Cipla's Price Target to INR1,120 From INR1,170, Keeps at Underperform	MT
Apr. 24	ICICI Securities Upgrades Cipla to Buy from Add; Price Target is INR1,550	MT
Jan. 27	Nomura Adjusts Cipla's Price Target to INR1,510 From INR1,770, Keeps at Buy	MT
Jan. 26	Jefferies Downgrades Cipla to Underperform From Hold, Adjusts Price Target to INR1,170 From INR1,630	MT
Nov. 03	Nomura Adjusts Cipla's Price Target to INR1,770 From INR1,810, Keeps at Buy	MT
25-10-31	Choice Equity Downgrades Cipla to Add from Buy; Price Target is INR1,700	MT
25-10-31	Choice Equity Downgrades Cipla to Reduce from Add, Price Target is INR1,580	MT
25-10-31	Phillip Securities Upgrades Cipla to Neutral from Sell; Price Target is INR1,420	MT
25-10-31	Prabhudas Lilladher Downgrades Cipla to Accumulate from Buy, Price Target is INR1,675	MT
25-10-31	JM Financial Downgrades Cipla to Reduce from Hold; Price Target is INR1,600	MT
25-07-29	Nomura Adjusts Cipla's Price Target to INR1,810 From INR1,780, Keeps at Buy	MT
25-05-14	Jefferies Adjusts Cipla's Price Target to INR1,610 From INR1,580, Keeps at Hold	MT
25-01-31	Nomura Adjusts Cipla's Price Target to INR1,780 From INR1,800, Keeps at Buy	MT
25-01-29	Jefferies Adjusts Cipla's Price Target to INR1,580 From INR1,560, Keeps at Hold	MT
24-11-05	Nomura Upgrades Cipla to Buy From Neutral, Adjusts Price Target to INR1,800 From INR1,568	MT
24-10-30	Jefferies Adjusts Cipla's Price Target to INR1,480 From INR1,450, Keeps at Hold	MT
24-07-29	Jefferies Adjusts Cipla's Price Target to INR1,450 From INR1,400, Keeps at Hold	MT

More recommendations

Generic Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
CIPLA LIMITED				+8.18%
SUN PHARMACEUTICAL INDUSTRIES LTD.				+14.36%
OTSUKA HOLDINGS CO., LTD.				+22.69%
ZYDUS LIFESCIENCES LIMITED				+3.36%
KRKA, D. D.				-6.24%
GEDEON RICHTER				+1.95%
ONO PHARMACEUTICAL CO., LTD.	-			+3.71%
GLENMARK PHARMACEUTICALS LIMITED				+1.87%
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.		-	-	-
AJANTA PHARMA LIMITED				+7.04%
Average				+6.33%
Weighted average by Cap.				+11.93%